论文部分内容阅读
CD70是一种属于肿瘤坏死因子(TNF)超家族的Ⅱ型跨膜蛋白,其受体CD27是分子量为55 k Da的I型跨膜糖蛋白。CD70主要表达于活化的T细胞、B细胞及成熟的树突状细胞(dendritic cell,DC)中,然而在病理状态下CD70却高表达于多种肿瘤组织中。目前以CD70为靶点的免疫治疗药物已经应用于临床前期研究。脑胶质瘤是中枢神经系统最常见的恶性肿瘤,CD70在肿瘤细胞表面的表达,既可使肿瘤细胞逃避免疫监视、诱导免疫细胞凋亡,同时也可以激活部分免疫细胞杀伤肿瘤细胞,这些研究给胶质瘤免疫治疗带来了新的方向。本文就近年来CD70在肿瘤尤其是胶质瘤研究中的进展做一综述,以期为CD70在胶质瘤的免疫治疗方面提供参考和研究依据。
CD70 is a type II transmembrane protein belonging to the superfamily of tumor necrosis factor (TNF) whose receptor CD27 is a type I transmembrane glycoprotein with a molecular weight of 55 kDa. CD70 is mainly expressed in activated T cells, B cells and mature dendritic cells (DCs). However, CD70 is highly expressed in many tumor tissues under pathological conditions. The current immunotherapy with CD70 as a target has been used in preclinical studies. Glioma is the most common malignant tumor of the central nervous system. The expression of CD70 on the surface of tumor cells not only can make tumor cells escape immune surveillance, induce apoptosis of immune cells, but also activate part of immune cells to kill tumor cells. These studies To glioma immunotherapy has brought a new direction. In this paper, we review the progress of CD70 in glioma in recent years, in order to provide a reference and research basis for CD70 immunotherapy in glioma.